B Vitamins Lower Homocysteine, but Large Trials Did Not Prevent More Heart Events
Learn what HOPE-2 and NORVIT found about folic acid, vitamins B6 and B12, homocysteine, stroke signals, and cardiovascular outcomes.

Folic acid, B6, and B12 reliably lowered homocysteine in major trials, but that biomarker change did not reduce the main composite cardiovascular outcomes.
The biomarker hypothesis
Higher blood homocysteine has been associated with cardiovascular risk, and folic acid plus vitamins B6 and B12 can lower it. That combination created a logical prevention hypothesis: if the marker falls, events might fall too. Randomized outcome trials were needed because an associated marker is not automatically a causal treatment target.
B vitamins also have established nutritional roles, and deficiency can require treatment. A neutral cardiovascular trial does not make the nutrients unnecessary. It shows that pharmacologic supplementation for event prevention is a separate question from meeting dietary needs or correcting a documented deficiency.

HOPE-2 lowered homocysteine without lowering the primary outcome
HOPE-2 randomly assigned 5,522 adults with vascular disease or diabetes to folic acid, vitamin B6, and vitamin B12 or placebo for about five years. Homocysteine fell in the active group, but the primary composite of cardiovascular death, myocardial infarction, and stroke was not significantly reduced.
Stroke occurred less often in the vitamin group, while unstable-angina hospitalization occurred more often. These were secondary findings within a neutral primary trial. They deserve research and careful interpretation, not a broad claim that a B-complex prevents cardiovascular disease.
NORVIT tested supplementation after myocardial infarction
NORVIT enrolled patients after acute myocardial infarction and assigned folic acid plus B12, B6 alone, the combination, or placebo. Treatment lowered homocysteine as expected but did not reduce recurrent cardiovascular disease. The investigators advised against using the tested regimen for secondary prevention after myocardial infarction.
The trial occurred in Norway, where folic-acid fortification differs from the United States. Baseline nutrition and food policy can modify how a supplement changes status. Those contextual differences matter, but they do not justify ignoring a failed clinical endpoint while advertising the successful biomarker change.
Why lowering a marker can fail
Homocysteine may partly reflect kidney function, nutrition, genetics, inflammation, or other processes rather than acting as a single reversible cause. Intervention timing may also matter if vascular disease is already established. Finally, a vitamin can influence several pathways, so the net clinical effect cannot be inferred from one laboratory measurement.
This principle appears throughout nutrition science. LDL, blood pressure, and deficiency markers differ in how strongly intervention-linked changes predict outcomes. The appropriate test is not whether a number moved, but whether the specific intervention improved patient-important endpoints with acceptable safety.

High doses are not ordinary nutrition
The trial doses exceeded standard dietary requirements. High supplemental folic acid can mask the blood signs of vitamin B12 deficiency while neurologic injury progresses, and high long-term vitamin B6 intake can cause nerve damage. Supplement facts panels should be reviewed across multivitamins, energy products, and standalone B complexes.
Older adults, vegans, people with malabsorption, and users of certain medicines may have legitimate B12 questions, but testing and treatment should target that problem. A product intended to correct deficiency should not be marketed as proven cardiovascular prevention when the event trials did not show that benefit.
The practical reading
Do not use homocysteine reduction alone as evidence that a supplement prevents heart attack. Ask whether a claim refers to a laboratory change, a prespecified cardiovascular endpoint, or a secondary stroke result. Those are different levels of evidence and should be labeled accordingly.
People with vascular disease should continue proven risk-reduction measures and discuss any high-dose B-vitamin regimen with their clinician. HOPE-2 and NORVIT provide a clear lesson: moving a plausible biomarker can be real while the promised clinical benefit remains absent.
Fortification changes the background
The United States fortifies enriched grain products with folic acid, so many adults begin with higher folate exposure than populations without fortification. That can reduce the room for an additional supplement to help and makes trial location relevant to interpretation.
Genetic variants affecting folate metabolism are often used in personalized-supplement marketing, but a genotype does not automatically establish that high-dose vitamins prevent events. Clinical decisions should integrate diet, laboratory findings, symptoms, medicines, and proven outcome evidence rather than one variant or homocysteine value. Replication in a population with a defined deficiency would answer a different and more targeted question.
Sources & further reading
This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.